MAGI2 Gene Region and Celiac Disease by Jauregi Miguel, Amaia et al.
ORIGINAL RESEARCH
published: 19 December 2019
doi: 10.3389/fnut.2019.00187
Frontiers in Nutrition | www.frontiersin.org 1 December 2019 | Volume 6 | Article 187
Edited by:
Carmen Gianfrani,
Institute of Biochemistry and Cell
Biology (CNR), Italy
Reviewed by:
Yanfei Zhang,
Geisinger Health System,
United States
Xiaofei Sun,
University of California, San Francisco,
United States
Giovanna Del Pozzo,
Institute of Genetics and Biophysics
(CNR), Italy
*Correspondence:
Ainara Castellanos-Rubio
ainara.castellanos@ehu.eus
Jose Ramón Bilbao
joseramon.bilbao@ehu.eus
Specialty section:
This article was submitted to
Nutritional Immunology,
a section of the journal
Frontiers in Nutrition
Received: 29 August 2019
Accepted: 03 December 2019
Published: 19 December 2019
Citation:
Jauregi-Miguel A, Santin I,
Garcia-Etxebarria K,
Olazagoitia-Garmendia A,
Romero-Garmendia I,
Sebastian-delaCruz M, Irastorza I,
Spanish Consortium for the Genetics
of Celiac Disease,
Castellanos-Rubio A and Bilbao JR
(2019) MAGI2 Gene Region and
Celiac Disease. Front. Nutr. 6:187.
doi: 10.3389/fnut.2019.00187
MAGI2 Gene Region and Celiac
Disease
Amaia Jauregi-Miguel 1, Izortze Santin 2,3, Koldo Garcia-Etxebarria 1,
Ane Olazagoitia-Garmendia 1, Irati Romero-Garmendia 1, Maialen Sebastian-delaCruz 1,
Iñaki Irastorza 4, Spanish Consortium for the Genetics of Celiac Disease,
Ainara Castellanos-Rubio 1,5* and Jose Ramón Bilbao1,3*
1 Department of Genetics, Physical Anthropology and Animal Physiology, Biocruces-Bizkaia Health Research Institute,
University of the Basque Country (Universidad del País Vasco/Euskal Herriko Unibertsitatea), Leioa, Spain, 2 Department of
Biochemistry and Molecular Biology, Biocruces-Bizkaia Health Research Institute, University of the Basque Country
(Universidad del País Vasco/Euskal Herriko Unibertsitatea), Leioa, Spain, 3 CIBER in Diabetes and Associated Metabolic
Diseases, Madrid, Spain, 4 Department of Pediatrics, Biocruces-Bizkaia Health Research Institute, Cruces University Hospital,
University of the Basque Country (Universidad del País Vasco/Euskal Herriko Unibertsitatea), Barakaldo, Spain, 5 Ikerbasque,
Basque Foundation for Science, Bilbao, Spain
Celiac disease (CD) patients present a loss of intestinal barrier function due to structural
alterations in the tight junction (TJ) network, the most apical unions between epithelial
cells. The association of TJ-related gene variants points to an implication of this network
in disease susceptibility. This work aims to characterize the functional implication of
TJ-related, disease-associated loci in CD pathogenesis. We performed an association
study of 8 TJ-related gene variants in a cohort of 270CD and 91 non-CD controls.
The expression level of transcripts located in the associated SNP region was analyzed
by RT-PCR in several human tissues and in duodenal biopsies of celiac patients and
non-CD controls. (si)RNA-driven silencing combined with gliadin in the Caco2 intestinal
cell line was used to analyze the implication of transcripts from the associated region
in the regulation of TJ genes. We replicated the association of rs6962966∗A variant
[p = 0.0029; OR = 1.88 (95%1.24–2.87)], located in an intron of TJ-related MAGI2
coding gene and upstream of RP4-587D13.2 transcript, bioinformatically classified as
a long non-coding RNA (lncRNA). The expression of both genes is correlated and
constitutively downregulated in CD intestine. Silencing of lncRNA decreases the levels
of MAGI2 protein. At the same time, silencing ofMAGI2 affects the expression of several
TJ-related genes. The associated region is functionally altered in disease, probably
affecting CD-related TJ genes.
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INTRODUCTION
Celiac disease (CD) is a chronic enteropathy, characterized by villous atrophy and inflammation of
the intestinal mucosa, that develops in genetically predisposed individuals. The disease is caused
by an inappropriate immune response to ingested gluten, a protein consisting of soluble gliadin
and insoluble glutenin components that is found mostly in wheat, but also in barley, rye and oat.
There is evidence supporting that various environmental factors, such as repeated gastrointestinal
infections (1, 2) or early infant feeding (3, 4) may also contribute to triggering the disease. A lifelong
gluten-free diet (GFD) is the only effective treatment for CD that achieves complete remission of
the symptoms.
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CD is a complex genetic disorder, and multiple genes
contribute to disease risk. The most important genetic
determinants, Human Leukocyte Antigen (HLA) molecules
HLA-DQ2 and HLA-DQ8, are necessary but not sufficient to
explain the predisposition to CD. Genome wide association
(GWA) and follow-up genetic studies have identified several
additional genomic regions associated to the disease, which
probably contain CD susceptibility genes, but our understanding
of the disease pathogenesis is still limited (5).
In fact, the majority of single-nucleotide polymorphisms
(SNPs) associated with increased disease risk are located in
non-coding regions of the genome (6–8). Some of them
map to long non-coding RNAs (lncRNAs) transcripts longer
than 200 bases in length, with no protein-coding potential,
that have been described to participate in genomic regulation
(9). The analysis of the expression profiles of lncRNAs on
autoimmune disease-associated regions has shown that they
are enriched in autoimmune-disease loci, suggesting that
they may be crucial to explain GWAS findings (10, 11).
Although their mechanisms of action are diverse and still not
very well-characterized, lncRNAs regulate gene expression at
transcriptional and post-transcriptional levels and are involved
in a range of developmental processes, adding complexity to
our understanding of how gene expression is regulated (12).
On the other hand, expression quantitative trait loci (eQTL)
analyses have demonstrated that certain SNPs associated with
complex diseases can affect the expression of lncRNAs, and thus
lncRNA genes can be considered candidate genes for disease-
susceptibility (13). In the case of CD, it has recently been shown
that a lncRNA in the IL18RAP locus that harbors a disease-
associated SNP is a key regulator of genes involved in the NFκB
pathway, which is known to be constitutively activated in the
small intestine of patients with CD (14, 15).
Apart fromGWAS studies, pathway analyses contribute to the
reconstruction of altered biological networks that are potentially
pathological and could help identify functional candidates that
participate to the genetic susceptibility. In the case of CD,
although an aberrant immune response is the main force
driving the disease, whole genome expression analyses have
identified important dysfunctions of other complex biological
processes that could be involved in CD development, including
alterations in the expression of genes related to intestinal
permeability (16–20). Impairment of the epithelial barrier and
increased permeability have been shown to be implicated in the
development of CD (20) and other gastrointestinal inflammatory
diseases like Crohn’s Disease (21) and Ulcerative Colitis (22).
Abbreviations: BSA, Bovine serum albumin; CD, Celiac disease; CEGEC, Spanish
Consortium for the Genetics of Celiac Disease; CPAT, Coding potential assessment
tool; DsiRNA, Dicer-substrate short interfering RNAs; EST, expressed sequence
tag; eQTL, Expression quantitative trait loci; GFD, Gluten-free diet; GWA,
Genome wide association; HLA, Human Leukocyte Antigen; IBD, Inflammatory
bowel disease; lncRNA, Long non-coding RNA; OR, Odds ratio; ORF, Open
reading frame; PhyloCSF, Phylogenetic Codon Substitution Frequencies; PT-BSA,
Pepisn-trypsin digested BSA; PTG, Pepsin-trypsin digested gliadin; RT-qPCR,
Quantitative reverse transcription PCR; si-RNA, Small interfering RNA; SNP,
Single-nucleotide polymorphism; TBS-T, Tris-buffered saline with Tween; TJ,
Tight Junction; TLR, Toll-like receptor; WB, Western blot.
The permeability of the intestinal epithelium is dependent on
the regulation of intercellular tight junctions (TJ), a continuous,
circumferential, belt-like structure at the luminal end of the
intercellular space that functions as a barrier. Changes in the
expression, distribution, and phosphorylation of TJ proteins
have been observed in CD and malfunction of this pathway
could have an important role in the augmented intestinal
permeability observed in the disease (23, 24). These alterations
persist in asymptomatic CD patients who are on GFD (25) and
ultrastructural and functional abnormalities in TJs appear also
in antibody-negative, asymptomatic first-degree relatives (26),
supporting a genetic origin of the pathway alterations and a
possible role in the initial stages of the disease. Different studies in
European populations have found polymorphisms in several TJ
genes, including adapter proteins MAGI2 and PARD3, together
withMYO9B, a cytoskeleton protein involved in TJ assembly, that
are associated with CD (27–29).
The MAGI proteins (Membrane Associated Guanylate-kinase
proteins with Inverted domain arrangement) are evolutionarily
conserved scaffolding proteins with several protein–protein
interaction domains to coordinate signaling complexes (30).
MAGI-2 protein (also known as AIP1/S-SCAM/ARIP1) is mainly
expressed in the brain at synaptic junctions but has also been
identified in the TJ plaque, where it controls epithelial integrity.
Interestingly, apart from the association with CD, linkage
analyses have shown that MAGI2 is located in a genomic region
harboring susceptibility genes for IBD (31).
With this on mind, we hypothesized that TJ genes could be
relevant candidates for gut disorders and specifically for CD.
Thus, the aim of the study was to replicate previous association
results and to perform gene expression and functional analyses of
the potential candidate genes in the associated regions.
MATERIALS AND METHODS
Duodenal Biopsies and Cell Culture
CD was diagnosed at the Pediatric Gastroenterology Clinic
(Cruces University Hospital), according to the European Society
for Pediatric Gastroenterology, Hepatology, and Nutrition
criteria in force at the time of recruitment. The study
was approved by the ethics committee of Cruces University
Hospital (ref. CEIC-E08/59, CEIC-E13/20, and CEIC-E16/46)
and informed consent was obtained from patients or their
parents. A total of 48 duodenal biopsy samples were taken from
32 patients divided in 3 categories: 16 biopsies from CD patients
at the time of diagnosis (symptomatic and on a gluten-containing
diet; 10 girls/6 boys; mean age at diagnosis 2.9 years, range 1.3–
9.3 years), 16 biopsies from the same patients after at least 2
years on strict GFD (asymptomatic, antibody negative, and with a
recovered intestinal epithelium) and 16 samples from non-celiac
individuals (5 girls/11 boys; mean age 7.7 years, range 1.1–13.0
years) who had been subjected to endoscopy but had no signs
of gut inflammation. After collection, samples were immediately
frozen and stored in liquid nitrogen until use.
The C2BBe1 human colon carcinoma cell line (clone of Caco-
2) was selected as a well-established in vitro model to study
the tight junctions in CD (32, 33). Cells were maintained in
Frontiers in Nutrition | www.frontiersin.org 2 December 2019 | Volume 6 | Article 187
Jauregi-Miguel et al. MAGI2 Gene Region and CD
DMEM supplemented with 10% heat inactivated FBS, 1% non-
essential amino acids and 1% penicillin-streptomycin) in tissue
culture flask.
Association Study
DNA samples from 270 celiac patients and 91 unselected blood
donors from the CEGEC (Spanish Consortium for Genetics
of Celiac Disease) collection were used for the association
study. DNA samples were extracted from whole blood using
conventional methods and stored at −80◦C until use. The
CEGEC study was approved by the Ethics Committees or
Institutional Review Board of all participating institutions.
Samples were genotyped in the BioMark HDTM platform at the
Sequencing and Genotyping Unit of the University of the Basque
Country (UPV/EHU). Fluidigm SNP assays were designed
according to the protocols recommended by the manufacturer
(Fluidigm Corporation, San Francisco, CA, USA) (Table S1).
We selected 3 SNPs in the MAGI2 locus, 2 in PARD3, and 3
in MYO9B, based on previously published association results
(29, 34, 35). The SNP Genotyping Analysis software by Fluidigm
was used for genotype calling. Clusters were evaluated manually,
and doubtful calls were recalled or rejected. To ensure population
homogeneity, an identity-by-state analysis and multidimensional
scaling were performed before standard χ2 association analysis
using Plink 1.07 (36).
Analysis of Coding Potential of
RP4-587D13.2
The protein-coding capacity of RP4-587D13.2 was evaluated in
silico. All possible open reading frames (ORFs) were identified
using ORF Finder (NCBI) (37) and the coding potential of the
transcript was assayed with Phylogenetic Codon Substitution
Frequencies (PhyloCSF) based on phylogenetic conservation
(38), as well as with the coding potential assessment tool (CPAT)
that uses a model built with open reading frame size and coverage
together with codon and hexamer usage bias (39).
Cellular Fractionation
To analyze the distribution of RP4-587D13.2 RNA in the nuclear
and cytoplasmic cell compartments of C2BBe1 cells, nuclei were
isolated using hypotonic lysis buffer (10mM Hepes, 10mM KCl,
0.1mM EDTA and %0.8 Triton-X) as previously described. For
relative quantification, the amounts of nuclear RP4-587D13.2,
Lnc13 (nuclear control) and RPLP0 (cytoplasmic control) RNA
were measured by RT-QPCR and compared to the amount of
each RNA in whole cells.
Cell Dicer-Substrate Short Interfering
RNAs (DsiRNAs) Transfection and Gliadin
Exposure
For in vitro cell transfection and gliadin stimulation, 5
× 104 cells/well were seeded in 24-well plates with 500
µl of supplemented medium without antibiotics. Reverse
transfection was performed with 30 nM of DsiRNA against
human MAGI2 (IDT corp. Cat. No. hs.Ri.MAGI2.13.1), RP4-
587D13.2 (5′ -GCAGUUUAAUAUCAUGUAUUGAAAA-3′) or
negative control DsiRNA (IDT corp. Cat. No. 51-01-14-
01) using Lipofectamine RNAimax reagent (Thermo Fisher
Scientific, Waltham, MA, USA) and following the manufacturer’s
instructions. Samples were incubated overnight in 5% CO2 at
37◦C before adding freshmediumwith antibiotic, then incubated
again for a total of 48 h from the start of transfection. Then
a well-established protocol was used to mimic gliadin-induced
inflammatory response in vitro (40–42). Cells were exposed to
1 mg/ml of pepsin-trypsin digested gliadin (PTG) or BSA (PT-
BSA) for 4 h and harvested for RNA or protein extraction.
Pepsin-trypsin digest of gliadin (PTG) (Merck, Darmstadt,
Germany 1.07185; 9002-07-7, and G3375-25, respectively) was
prepared as described previously (43). An enzymatic digest of
BSA (PT-BSA) was prepared in the same way and used as a
negative control of stimulation.
Protein Extraction and Immunoblot
Analysis
Whole cell extracts were directly lysed into 2x Laemmli
Sample buffer containing 5% β- mercaptoethanol and stored
at −20◦C until use. Total protein extracts were heat-treated at
95◦C for 5min, fractionated by SDS-PAGE and transferred to
nitrocellulose membranes using the Trans-Blot Turbo Transfer
apparatus (BioRad, Hercules, California, USA). After incubation
with 5% non-fat milk in Tris-buffered saline with 0.05% Tween
(TBS-T) for 1 h, the membrane was incubated at 4◦C overnight
with polyclonal antibodies against MAGI2 (1:500) (ABCAM,
Cat. No. ab97343) and β-Tubulin (1:1,000) (ABCAM, Cat. No.
ab18207). Membranes were washed three times for 10min and
incubated with horseradish peroxidase-conjugated anti-mouse
(1:2,000) or anti-rabbit (1:10,000) antibodies for 1 h at room
temperature in 5% BSA in TBS-T (Jackson ImmunoResearch
Laboratories, Inc.; Cat No. 111-035-003 and 115-035-003,
respectively). Blots were washed with TBS-T three times and
visualized using SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher, Cat No. 34094) on the ChemiDoc MP
system (BioRad, Hercules, California, USA). The quantification
of band intensities was done using the Image Lab 4.1 software
and results were normalized to β-tubulin.
RNA and DNA Isolation From Tissue
Samples and Cultured Cells
Total RNA andDNAwere prepared with theNucleoSpin RNA kit
and NucleoSpin Blood kit, respectively (Macherey-Nagel, Düren,
Germany) according to the protocols provided. Frozen biopsy
samples were disrupted with disposable plastic pellet pestles prior
to nucleic acid extraction. Cells were lysed and homogenized
using the buffers supplied with the kits. The concentration and
purity of the RNA and DNA were determined by UV absorbance
at 260 nm on a NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA) and samples were stored
at −80◦C until use. To determine the expression of MAGI2
and RP4-587D13.2 across different human tissues, a commercial
Human Total RNA Master Panel II (Clontech Laboratories, Inc.,
Cat. No. 636643) was used.
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TABLE 1 | Association analysis of single nucleotide polymorphisms in TJ-related candidate genes in CD.
SNP Position (Hg38) Gene Minor allele CD MAF Control MAF p-value Odds-ratio (CI 95%)
rs6962966 chr7: 78174806 MAGI2 A 0.5210 0.3661 0.0029 1.88 (1.24–2.87)
rs9640699 chr7: 78366115 MAGI2 A 0.3613 0.3056 0.1763 1.29 (0.89–1.85)
rs1496770 chr7: 78629694 MAGI2 T 0.4699 0.4341 0.4022 1.16 (0.82–1.62)
rs10763976 chr10: 34275364 PARD3 G 0.4713 0.4560 0.7246 1.06 (0.76–1.49)
rs4379776 chr10: 34328092 PARD3 T 0.3811 0.4286 0.2583 0.82 (0.58–1.16)
rs2305767 chr19: 17183487 MYO9B C 0.3547 0.3956 0.3311 0.85 (0.59–1.19)
rs1457092 chr19: 17193427 MYO9B A 0.3940 0.3889 0.9042 1.02 (0.72–1.45)
rs2305764 chr19: 17203024 MYO9B A 0.4147 0.4333 0.6710 0.93 (0.65–1.32)
Significant association values (p < 0.05) are shown in bold.
Chr, chromosome; SNP, single nucleotide polymorphism; MAF, minor allele frequency; CD, Celiac disease; OR, odds ratio; CI, confidence interval.
Expression Analyses
The expression of MAGI2 and RP4-587D13.2 was analyzed
in biopsy samples and caco2 cells. Total RNA was reverse
transcribed with the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories, Inc. Berkeley, CA, USA). Expression
of MAGI2 mRNA was determined by real-time (RT)-
PCR using specific TaqMan Gene Expression Assays
(thermoFisher Scientific) in a Eco Real-Time PCR System
(Illumina, Inc., San Diego, CA, USA). The expression of
RP4-587D13.2 lncRNA was measured using custom-designed
primers (F: 5′-GGTGCTGGAAATTCATCAGTG-3′; R: 5′-
TGACCACATGACTGACACCA-3′) and Quantitect SYBR
Green master mix (Qiagen, Hilden, Germany). The specificity
of the primers was tested by in-silico PCR on the University of
California Santa Cruz web server (http://genome.ucsc.edu/cgi-
bin/hgPcr) and melting curve analysis were performed in all
qPCR reactions.
The expression levels of TJ-related genes were measured
by RT-PCR on a Fluidigm BioMark dynamic array system
following the 48.48 Fast Real-Time PCR Workflow (Fluidigm
Corporation, San Francisco, CA, USA). Candidate genes with
central functions in the TJ and TJ-related Toll Like Receptor
(TLR) networks according to the KEGG database (http://
www.genome.jp/kegg) were selected (Table S2). The reverse
transcribed cDNA from each sample was preamplified using
the Fluidigm Gene Expression Specific Target Amplification kit
(Fluidigm Corporation, San Francisco, CA, USA) and amplified
using TaqMan Universal PCR master mix (Thermo Fisher
Scientific, Waltham, MA, USA). Complete results are available
at the Gene Expression Omnibus (https://www.ncbi.nlm.nih.
gov/geo/) with accession number GSE84729. The expression of
the housekeeping gene RPLP0 (large ribosomal protein) was
quantified in each experiment and used as an endogenous
control of input RNA. The relative expression of each gene
was calculated using the accurate Ct method as previously
described (44).
The Commercial TaqMan assays probes (Thermo
Fisher Scientific, Waltham, MA, USA) used for expression
analyses are listed in Table S2. Probes that spanned an
exon–exon junction were chosen to avoid the detection of
genomic DNA.
SNP Genotyping
In order to determine whether the risk attributed to the newly
identified variant rs6962966 was related to gene expression in
CD patients, the tag SNP rs2691527 (r2 = 1 with associated SNP
rs6962966) was genotyped in the duodenal biopsy samples on
a Eco Real-Time PCR System (Illumina, Inc., San Diego, CA,
USA) using a predesigned TaqMan Genotyping assay (Thermo
Fisher Scientific, Assay ID 4351379) and TaqMan genotyping
Mastermix (Thermo Fisher Scientific, Waltham, MA, USA).
Analysis of Results
Statistical analyses were carried out using GraphPad Prism
version 5.0 software (GraphPad Software Inc, La Jolla, CA, USA)
to assess differences among groups. Non-parametric, paired
(Wilcoxon matched-pairs test) tests were performed for the
comparison of the expression levels between CD patients at
diagnosis and after 2 years on GFD, and the Mann–Whitney
U test was used to compare each disease group to the controls
and unpaired t test to in the silencing experiments. Coexpression
was assessed with Spearman’s correlation test. Heat-maps were
constructed using the FiRe Macro v2.2 for Microsoft Excel
from the University of Fribourg available at http://www.unifr.ch/
plantbio/FiRe/main.html. Only 2-tailed p-values below 0.05 were
considered significant.
RESULTS
An Intronic Polymorphism in MAGI2 Is
Associated to CD
We analyzed 8 SNPs located in MAGI2, PARD3, and MYO9B,
previously associated with CD. Their frequencies in CD patients
and controls are listed on Table 1. We detected an association
between SNP rs6962966 (GRCh38/hg38; chr7:77,804,123) in an
intronic region of MAGI2 and CD risk. The SNP was in Hardy-
Weinberg equilibrium in the control group and the frequency of
the minor allele was higher in patients, augmenting the risk to
develop CD 1.88-fold (95%CI= 1.24–2.87; p= 0.0029). No other
SNPs inMAGI2, PARD3, orMYO9B were associated with CD.
In order to characterize the effects of the associated intronic
SNP on disease risk, we analyzed its genomic context in
search for putative regulatory elements that could be affected
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FIGURE 1 | Genomic context of CD associated SNP rs6969266. The reference sequence of MAGI2 (NCBI) and genomic annotations of a 20-kb region around
candidate SNP rs6962966 are shown.
FIGURE 2 | Characterization of RPL4-587D13.2 expression in human tissues and the C2BBe1 cell line. (A) mRNA expression of MAGI2 and RPL4-587D13.2 in RNA
from 9 human tissues. Values are represented relative to the tissue with the highest expression levels (brain). (B) Subcellular localization of RPL4-587D13.2 in C2BBe1
cells. The box-plots show the ratio of nuclear to whole cell transcripts, represented as the maximum and minimum values and the mean (n = 3); LNC13 and RPLP0
are used as nuclear and cytoplasmic controls, respectively. (C) Representative western blot and (D) quantification of MAGI2 protein levels in C2BBe1 cells silenced for
RPL4-587D13.2 (siRNA_1 and siRNA_2). The mean and standard deviation of MAGI2 expression relative to the control siRNA are shown (n = 3) (*0.01 < p < 0.05).
causing alterations in gene regulation. An analysis of current
UCSC Genome browser annotations showed that protein-
coding gene MAGI2 hosts different types of non-coding genes,
including processed transcripts, pseudogenes, and RNA genes.
The great majority of them are located in introns and no
specific function or effect on their host gene have been
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described so far. As an exception, the antisense gene MAGI2-
AS3 overlaps the first exon of MAGI2 and has been recently
linked to breast cancer (45). Regarding the intron where the
CD-associated rs6962966 SNP falls, we found that it also
harbors a non-characterized transcript, named RP4-587D13.2
(Figure 1).
RP4-587D13.2 Is a Long Non-coding
Transcript That Can Regulate MAGI2
Expression
In order to characterize the region around the associated
SNP, we performed expression analysis of both RP4-587D13.2
and MAGI2 across different human tissues. The results
showed that these transcripts are ubiquotiusly expressed in
all human tissues analyzed, including the intestine, the CD
target tissue, and are predominantly expressed in brain
(Figure 2A). It can be observed that both present a similar
expression pattern and are positively correlated (p = 0.0007)
across tissues. We next evaluated the protein-coding capacity
of RP4-587D13.2 in silico using three different approaches.
Overall, the lack of functional ORFs as well as the low
phylogenetic conservation and coding probability of the region
suggests that RP4-587D13.2 is a long non-coding transcript
(Table S3).
The cellular localization of the lncRNA was evaluated in
C2BBe1 intestinal human cells, and results revealed that RP4-
587D13.2 accumulates preferentially in the nucleus (Figure 2B).
The nuclear localization of RP4-587D13.2 together with its
coexpression with the neighboring MAGI2 suggests that this
lncRNA could contribute to the regulation ofMAGI2 expression.
To test this hypothesis, we performed siRNA silencing of RP4-
587D13.2 in C2Bbbe1 intestinal cells using two different siRNAs.
We managed to reduce the expression of RP4-587D13.2 by 46%
in intestinal cells (Figure S1) which in turn resulted in a 56%
decrease in MAGI2 protein (Figures 2C,D), confirming that this
lncRNA is somehow affecting the regulation of the coding gene.
PTG Stimulation Alters the Expression of
TJ-Related Genes in MAGI2-Silenced Cells
In order to determine the functional significance of the MAGI2
region in the CD characteristic dysregulation of the TJ pathway,
the expression of a TJ-related gene panel was analyzed in the
FIGURE 3 | Effects ofMAGI2 silencing and gliadin on the expression of a TJ-related genes in C2BBe1 intestinal cells. (A)Western blot of MAGI2 protein upon silencing
in C2BBe1 cells. (B) Quantification of MAGI2 protein levels under different cell treatments, relative to control cells (transfected with control siRNA and incubated with
PT-BSA). Mean and standard deviation are shown (n = 3). (C) Heat map of candidate gene expression in different conditions; PTG stimulation, siRNA mediated MAGI2
silencing (MAGI2_si1) and PTG stimulation of MAGI2_si1 cells. Expression levels are shown as fold-change relative to the average of control samples (silenced with a
control siRNA and incubated with PT-BSA). Columns represent treatment categories and lines candidate genes (*0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001).
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FIGURE 4 | mRNA expression of (A) RPL4-587D13.2, (B) MAGI2, (C) CLDN2, and (D) ZAK in duodenal biopsies from CD patients at diagnosis (white dots), treated
CD patients (gray dots) and non-Celiac controls (black dots) represented as mean and SEM, relative to the average of the control samples (*0.01 < p < 0.05; **0.001
< p < 0.01).
C2BBe1 intestinal cell line. Due to the difficulty of efficiently
silencing the lncRNA, probably because of its nuclear location,
the effects in downstream gene expression were assessed by
MAGI2 silencing. As expected, the efficiency ofMAGI2 silencing
was above 59% (Figures 3A,B) and silenced cells showed altered
expression of CLDN1, F11R, PARD6A, PPP2R3A, TICAM2, and
ZAK (Figure 3C). Interestingly, upon PTG stimulation, there
was an additional decrease of MAGI2 and a stronger effect
on the TJ-related genes in MAGI2-silenced cells: the changes
observed in PARD6A and ZAK were more pronounced, and
alterations extended to other genes of the pathway, including
GNAI1 and CLDN2.
The Expression of MAGI2 and
RP4-587D13.2 Is Reduced in CD and Could
Explain Alterations of Other Tight Junction
Genes
Since the region harboring RP4-587D13.2 and MAGI2 is
associated to CD and we have observed that both genes can
influence the expression of other TJ-related genes, we analyzed
their expression in biopsies from CD patients and controls.
As shown in Figures 4A,B, both MAGI2 and RP4-587D13.2
show significantly lower expression levels in the duodenum of
active CD patients, and this downregulation persisted after GFD
treatment. The correlation between MAGI2 and RP4-587D13.2
gene expression previously observed in different human tissues
(Figure 2A) was also present in duodenal biopsies (r = 0.4033; p
= 0.027) (Figure S2).
In order to assess whether the TJ genes that are altered by the
downregulation of the MAGI2 region are also altered in CD, we
analyzed their expression in CD and control biopsies. Two of
the genes, CLDN2 and ZAK, are overexpressed in the intestine
of active CD patients (on a gluten containing diet) compared
to treated and control samples (Figures 4C,D), confirming what
had been previously observed in vitro (Figure 3C).
Despite the limited number of biological samples representing
all three genotypes in our study, we also searched for
relationships between the risk genotypes and the expression
level of the MAGI2 region genes. As the presence of all three
genotypes in every group was not possible, heterozygous, and
risk-allele homozygous samples were combined. The results of
eQTL analysis showed that the presence of the risk allele was
not significantly associated with decreased expression of either
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FIGURE 5 | eQTL analyses for (A) MAGI2 and (B) RP4-587D13.2 in duodenal biopsies from patients with CD and non-CD controls. Scatter plots show expression
relative to the control mean in patients lacking or harboring the tag SNP rs2691527*T allele. Spearman correlation between MAGI2 and RP4-587D13.2 expression
levels according to the (C) absence or (D) presence of tag SNP rs2691527*T allele.
transcript in the MAGI2 region (Figures 5A,B). However, when
we analyzed the correlation of both transcripts based on the
genotype we observed that the samples harboring the risk allele
showed a stronger correlation (r = 0.6364; p = 0.0402) than
those with no risk allele (r = 0.4286; p= 0.4194) (Figures 5C,D)
suggesting that the risk allele strengthens the interaction of both
genes thus affecting the regulation of downstream genes.
DISCUSSION
Polymorphisms in TJ-related genesMAGI2, PARD3, andMYO9B
that potentially influence the homeostasis of the intestinal barrier
have been associated with risk of gastrointestinal disorders
like CD and IBD (27, 29, 46). However, attempts to replicate
those associations in different cohorts have sometimes failed,
highlighting the heterogeneity and complexity of common
human disorders (34, 35, 47). In this study, we have been able
to replicate the association with rs6962966 (an intronic variant in
MAGI2), previously identified in Dutch and British cohorts (29),
in a Spanish CD cohort.
Human MAGI2 is a relatively large gene (∼1.5 Mbps)
that maps to chromosome 7q21 and encodes the membrane-
associated, guanylate kinase inverted 2 tight junction protein,
involved in epithelial integrity. The CD-associated allele has
been proposed to be involved in MAGI2 gene function, but no
studies have been performed to determine the possible effects of
the CD-associated polymorphism. The candidate gene selection
that follows SNP association studies is often aprioristic, and
functional studies are the only unbiased approach to characterize
the associated region. Therefore, in order to define the role of this
intronic variant in CD pathogenesis, we scrutinized the genomic
region around rs6962966 and found that, apart from the coding
geneMAGI2, the region also harbors RP4-587D13.2, a long RNA
transcript represented by a cluster of expressed sequence tags
(ESTs) covering 721 bp that maps 3,9 kb upstream (centromeric)
of the CD-associated SNP. In silico analysis showed that this
transcript is a long non-coding intronic RNA of unknown
biological function. Recent studies have evidenced that intronic
regions are key sources of regulatory non-coding RNAs that are
able to regulate the expression of other genes through diverse
mechanisms (48). Interestingly, the antisense lncRNA MAGI2-
AS3 overlapping the first exon of MAGI2 has been recently
related to tumor suppression in several cancers including breast,
lung and hepatocellular carcinoma (45, 49, 50). In the case of
lncRNA RP4-587D13.2, located within the intron harboring the
CD-associated rs6962966, both its differential tissue distribution
and preferential nuclear localization suggest that it is a functional,
regulatory transcript. Interestingly, RP4-587D13.2 and MAGI2
show a concordant expression profile across human tissues,
including the small intestine, indicating that RP4-587D13.2 could
be processed from the same pre-mRNA and could be functionally
related to MAGI2. Moreover, MAGI2 shows decreased protein
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levels upon silencing of this intronic lncRNA, suggesting that
RP4-587D13.2 could be involved in the transcriptional (or post-
transcriptional) regulation of MAGI2 expression and thus in the
coordination of the expression of genes that are relevant to the
TJ pathway. However, these regulatory relationships between the
intronic lncRNA and the protein transcribed by its host locus
MAGI2 must be confirmed and the mechanisms that underlie
such regulatory behaviors remain to be fully understood.
We observed that the expression of several TJ-related genes is
altered in an in vitromodel that mimics the context of CD, where
the expression of MAGI2 is repressed and intestinal cells are
exposed to digested gliadin (PTG), suggesting that both MAGI2,
and the upstream RP4-587D13.2 are necessary for a correct
function of the pathway. Moreover, the decrease in expression
of both genes, together with the alteration observed in several
other TJ genes in the disease tissue suggests that the MAGI2
region could be involved in the regulation of the network.
Interestingly, in the in vitromodel, gliadin stimulation enhanced
the effects of gene-silencing, resembling what is observed for
CLDN2 and ZAK in biopsy samples from active and treated
CD patients. On the other hand, the expression of MAGI2 and
RP4-587D13.2 is downregulated in the duodenum of active CD
patients and persists even after more than 2 years on GFD
and an apparent recovery from intestinal atrophy, supporting a
constitutive alteration that could have a genetic origin. However,
several other TJ genes that are altered in the PTG-challenged in
vitro model (and in active CD) are normalized in GFD-treated
patients, stressing the role of gluten-mediated induction of some
of the alterations. The constitutive alteration of gene expression
in the MAGI2 region could promote an increased response to
ingested gluten, probably leading to a higher disruption of TJ
structures and to an enhanced intestinal permeability. Overall,
the constitutive alteration of gene expression, together with the
presence of an associated genetic variant point to a dysfunction
that is present before the clinical onset of the disease, as has been
previously suggested for the enhanced intestinal permeability
that occurs in CD (25).
Several studies have described that more than half of the
disease-associated SNPs correlate with the expression of at least
one adjacent gene (51) acting as cis-eQTL. The eQTL analysis in
our samples did not find a link between the risk allele and the
reduction of MAGI2 or RP4-587D13.2 expression in intestinal
biopsy samples. However, there was a stronger correlation
between the expression of both genes in the presence of the risk
allele, suggesting that the associated SNP could be influencing
the regulation of MAGI2 exerted by RP4-587D13.2. The effects
of disease-associated SNPs go far beyond the simplistic idea of
transcriptional control of an adjacent locus and the complexity
of the mechanisms involved in the functional translation of
associated genetic variants make it difficult to explain their
role in the disease. Further functional studies and large meta-
analyses might be able to pinpoint the causal variants within a
disease-associated locus and determine their downstream effects
in greater detail (52).
In summary, we have demonstrated that theMAGI2 genomic
region is associated with CD and presents transcriptional
alterations that seem to be relevant for disease pathogenesis. We
postulate that RP4-587D13.2 is regulating MAGI2 expression,
that this relationship seems to be affected by the associated SNP
and that the constitutive reduced expression of both transcripts
in patients could affect the TJ pathway, which is crucial for
intestinal permeability, and enhance the response to the ingested
gluten. Further studies are needed to verify the functionality of
this intronic lncRNA and the complex regulatory relationships
between RP4-587D13.2, its host loci MAGI2 and disease. All
this will help to understand the complexity of the interactions
between the environmental trigger, genetic polymorphisms and
gene expression.
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